Reuters: Regulatory News: FDA rejects Aveo kidney cancer drug, asks for additional trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA rejects Aveo kidney cancer drug, asks for additional trial Jun 10th 2013, 10:42 June 10 | Mon Jun 10, 2013 6:42am EDT June 10 (Reuters) - Aveo Oncology said the U.S. Food and Drug Administration denied approval for its experimental kidney cancer drug citing inconsistent trial results and asked for an additional study. In a complete response letter to the company, the health regulator said inconsistent survival data from the drug tivozanib's trials made the results "uninterpretable and inconclusive."

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions